Comparative genomic medicine regulation

No single model fully resolves the challenges of genomic medicine. Strong regulation must protect patients without unnecessarily preventing responsible research or restricting equitable access to beneficial treatments.

5. Landmark case laws in comparative genomic medicine and genetic rights

Direct court decisions about clinical genome editing remain limited. The following cases address foundational questions of genetic privacy, reproductive autonomy, discrimination, bodily integrity, and biotechnology. They are relevant to genomic medicine even where they do not directly concern gene-editing treatment.

1. S. and Marper v. United Kingdom, Applications Nos. 30562/04 and 30566/04, European Court of Human Rights, Grand Chamber, 4 December 2008

Facts: The applicants challenged the retention of their fingerprints, cellular samples, and DNA profiles after criminal proceedings had ended without a conviction.

Legal issue: Whether retaining DNA material and profiles infringed the right to respect for private life under Article 8 of the European Convention on Human Rights.

Decision: The Court found a violation of Article 8. It emphasized the sensitive nature of genetic information and the need for safeguards governing its retention.

Principle: Genetic information is not merely an identifying code. It may reveal sensitive health and familial information and therefore requires meaningful privacy protection.

Relevance to genomic medicine: Health systems and biobanks should establish clear rules on retention, secondary use, access, and deletion of genetic data. Consent for one diagnostic purpose should not automatically authorize every future use.

2. Gaughran v. United Kingdom, Application No. 45245/15, European Court of Human Rights, 13 February 2020

Facts: The applicant challenged the indefinite retention of his fingerprints, photograph, and DNA profile following a conviction.

Legal issue: Whether the continued retention of personal identifying information without adequate differentiation or safeguards complied with Article 8.

Decision: The Court found a violation of Article 8, considering the absence of adequate limits and review safeguards for retention.

Principle: The public interest in retaining identifying information must be balanced against privacy, necessity, proportionality, and effective review.

Relevance: Genomic medicine produces information that may remain informative for a person's lifetime and potentially reveal information about relatives. Future systems should provide retention limits, access controls, and periodic review rather than assuming indefinite storage is always justified.

3. Reference re Genetic Non-Discrimination Act, 2020 SCC 17 — Supreme Court of Canada

Facts: Quebec challenged the constitutional validity of federal legislation restricting compulsory genetic testing and the forced disclosure of genetic-test results in specified contractual contexts.

Legal issue: Whether Parliament had constitutional authority to enact the Genetic Non-Discrimination Act under its criminal-law power.

Decision: The Supreme Court of Canada upheld Parliament's authority, though the judges differed in their reasoning.

Principle: Genetic discrimination is a legitimate subject of legal protection, and the constitutional allocation of legislative powers determines how such protection may be implemented.

Relevance: People may avoid medically beneficial testing if they fear that genetic information will be used against them. Effective regulation should protect genetic autonomy while clearly defining when the collection, use, or disclosure of genetic information is permitted.

4. Moore v. Regents of the University of California, 51 Cal. 3d 120 (1990) — California, United States

Facts: John Moore underwent treatment for leukaemia. Researchers developed a commercially valuable cell line from biological material obtained during his treatment, raising questions about disclosure, consent, and ownership.

Legal issue: Whether the patient could bring claims based on property rights in the excised cells and whether physicians owed disclosure duties concerning their research and financial interests.

Decision: The California Supreme Court rejected Moore's conversion claim based on ownership of the excised cells, but allowed claims concerning physicians' disclosure duties and informed consent to proceed.

Principle: A patient's interests in bodily autonomy and informed consent are distinct from a broad claim of continuing property ownership over removed biological material.

Relevance: Genomic medicine depends on tissue samples, sequencing data, and biobank contributions. Consent frameworks should explain research uses, commercial interests, potential benefits, and the extent of participants' control over stored samples and resulting data.

5. Washington v. Glucksberg, 521 U.S. 702 (1997) — United States

Facts: Physicians and terminally ill patients challenged Washington State's prohibition on assisted suicide.

Legal issue: Whether the Fourteenth Amendment protected a fundamental constitutional right to assistance in ending one's life.

Decision: The Supreme Court held that the asserted right was not a fundamental liberty interest protected by the Due Process Clause in the manner claimed.

Principle: Constitutional protection for bodily autonomy is interpreted within the jurisdiction's legal tradition and the specific right asserted; not every medical choice automatically becomes a fundamental constitutional right.

Relevance: Although the case did not concern genomics, it is useful in evaluating the limits of claims to medical autonomy. Regulation of genomic interventions must distinguish recognized rights to consent to treatment from claims to a right to demand any experimental or technologically possible intervention.

6. Jacobson v. Massachusetts, 197 U.S. 11 (1905) — United States

Facts: The case concerned a state smallpox vaccination requirement and the imposition of a penalty for refusing vaccination.

Legal issue: Whether a public-health vaccination law violated constitutional liberty.

Decision: The Supreme Court upheld the law in the circumstances, recognizing the state's authority to adopt reasonable public-health measures while acknowledging limits on that authority.

Principle: Individual liberty and bodily autonomy may be subject to properly justified public-health regulation, but state power is not unlimited.

Relevance: Genomic medicine regulation must balance individual choice, public health, and the rights of others. A genetic test or genomic intervention should not be compelled merely because it could be useful; any coercive measure requires a valid legal basis and appropriate safeguards.

7. Roe v. Wade, 410 U.S. 113 (1973) — United States

Facts: The case concerned constitutional limits on state regulation of abortion.

Legal issue: Whether the Constitution protected a right to terminate a pregnancy and how that right related to state interests.

Decision and current legal status: The Supreme Court recognized constitutional protection for abortion in 1973, but overruled Roe in Dobbs v. Jackson Women's Health Organization (2022). Roe is therefore historical precedent rather than the governing federal constitutional rule.

Relevance: The case remains part of the historical development of reproductive-autonomy jurisprudence, but contemporary genomic medicine must be analyzed under current law in the relevant jurisdiction. Questions involving embryo testing, prenatal genetic diagnosis, and reproductive decisions can be affected by changing statutory and constitutional frameworks.

8. Evans v. United Kingdom, Application No. 6339/05, European Court of Human Rights, Grand Chamber, 10 April 2007

Facts: After a relationship ended, a woman sought to use embryos created through in-vitro fertilization. The former partner withdrew consent, as permitted by the applicable UK legislation.

Legal issue: Whether the legal requirement for continuing consent to embryo use violated rights under Article 8 of the European Convention on Human Rights.

Decision: The Grand Chamber found no violation of Article 8.

Principle: Reproductive autonomy involves competing interests, and legal systems may require continuing consent from both genetic contributors in certain assisted-reproduction contexts.

Relevance: Genomic medicine often intersects with embryo testing, reproductive planning, and inherited disease prevention. Future frameworks need clear rules for consent, withdrawal, embryo storage, and disputes arising when reproductive intentions change.

9. Brüstle v. Greenpeace e.V., Case C-34/10, Court of Justice of the European Union, 18 October 2011

Facts: The case concerned the patentability of inventions involving human embryonic stem cells under European biotechnology patent law.

Legal issue: How the EU Biotechnology Directive's exclusion of uses of human embryos for industrial or commercial purposes should be interpreted.

Decision: The Court interpreted the exclusion broadly in the context of the patent claims before it, addressing the meaning of a human embryo and the limits of patentability.

Principle: Commercial incentives in biotechnology may be limited by legal commitments concerning human dignity and the protection of human embryos.

Relevance: Genomic medicine regulation must coordinate research incentives and intellectual property rights with ethical constraints. Patentability, however, is distinct from whether a treatment is clinically safe, authorized, or lawful to provide.

10. M/S United India Insurance Co. Ltd. v. Jai Parkash Tayal, Delhi High Court, 2018

Facts: The dispute concerned genetic testing and its implications for insurance-related decisions.

Legal issue: Whether genetic information could be used in a manner that raised concerns about discrimination, fairness, and the legal treatment of individuals with genetic predispositions.

Significance: The litigation brought genetic discrimination into the Indian legal debate, particularly in relation to insurance and the treatment of individuals based on genetic characteristics.

Important qualification: The judgment's operative effect was stayed by the Supreme Court. It should not be described as establishing a settled, comprehensive Indian prohibition on all forms of genetic discrimination.

Relevance: India could consider clearer statutory protection against unjustified genetic discrimination in insurance, employment, and access to services, while defining legitimate and proportionate uses of genetic information.

6. Core regulatory challenges

A. Informed consent and patient autonomy

Genomic tests can reveal information about present health, future disease risks, ancestry, and biological relatives. Patients should receive understandable explanations of the test's purpose, limits, possible incidental findings, and implications for family members.

Consent should be meaningful rather than a broad authorization hidden in lengthy forms. Where clinically appropriate, patients should be offered genetic counselling before and after testing.

B. Genetic privacy and data governance

Genomic information is unusually sensitive because it can remain relevant throughout a person's life and may reveal information about biological relatives who have not themselves consented to testing.

A sound legal framework should regulate:

Collection and use of genetic samples and sequence data.

Access by clinicians, laboratories, researchers, insurers, and employers.

Data sharing across borders.

Re-identification risks in supposedly anonymized datasets.

Retention, withdrawal, deletion, and secondary research use.

Security breaches and remedies for unauthorized disclosure.

Privacy protection must also recognize that complete anonymization of genomic data may be difficult in some circumstances.

C. Somatic gene therapy and heritable genome editing

The law should distinguish between two fundamentally different categories.

Somatic gene therapy targets cells in an individual patient and is generally intended to treat that patient's condition without transmitting the genetic change to descendants.

Heritable genome editing changes genetic material in ways that could be passed to future generations. It raises additional concerns about long-term safety, consent by people not yet born, unintended genetic effects, and social inequality.

Regulation should therefore require rigorous evidence of safety and efficacy for clinical interventions, while applying particularly stringent legal and ethical safeguards to heritable editing. The precise legal position differs among countries.

D. Genetic discrimination

Genetic information may be misused by insurers, employers, lenders, or other organizations to make decisions based on disease predispositions rather than present functional ability or legitimate risk factors.

Future legislation should define prohibited discrimination, establish appropriate exceptions, and provide accessible remedies. It should also distinguish genetic test results from other medical information where different legal rules apply.

E. Clinical trials and long-term monitoring

Gene therapies may have effects that persist for years. Clinical research should therefore include independent ethics review, reliable informed consent, adverse-event reporting, and long-term monitoring proportionate to the treatment's risks.

Regulators should also consider how responsibility is allocated among manufacturers, treating institutions, researchers, and clinicians when serious harm occurs.

F. Equitable access

Genomic treatments can be extremely expensive and may initially be available only in specialist centres. Legal frameworks should consider fair allocation, public funding, health insurance coverage, clinical eligibility, and access for underserved populations.

The objective should be to promote responsible innovation without allowing genomic advances to deepen existing inequalities in healthcare.

7. A future regulatory model

1. Safety and authorization

Require appropriate clinical evidence, independent review, manufacturing quality controls, and post-treatment surveillance.

2. Consent and autonomy

Provide understandable information, counselling where appropriate, and clear procedures for consent and withdrawal.

3. Genetic privacy

Establish strict access controls, purpose limitations, secure data-sharing rules, and remedies for misuse.

4. Anti-discrimination protections

Restrict unjustified use of genetic information in employment, insurance, and other consequential decisions.

5. Public accountability

Require transparent regulatory decisions, independent ethics oversight, accessible complaints procedures, and appropriate judicial review.

6. International cooperation

Improve standards for cross-border research, genomic data sharing, clinical-trial oversight, and responses to unsafe or unauthorized interventions.

8. Conclusion

Civil law and comparative future genomic medicine regulation frameworks must reconcile scientific progress with bodily autonomy, informed consent, privacy, equality, safety, and human dignity. The relevant legal rules are distributed across medical regulation, constitutional law, data protection, research ethics, reproductive law, intellectual property, and civil liability.

The cases discussed provide several important lessons:

S. and Marper and Gaughran illustrate the need for proportionate retention and protection of genetic information.

Reference re Genetic Non-Discrimination Act demonstrates the legal importance of protecting individuals against compulsory genetic testing and misuse of results.

Moore v. Regents highlights the relationship between informed consent, biological materials, and commercial research.

Evans v. United Kingdom demonstrates the complexity of reproductive autonomy and continuing consent.

Brüstle v. Greenpeace shows how ethical limits may affect biotechnology patentability.

United India Insurance Co. v. Jai Parkash Tayal illustrates the developing debate over genetic discrimination in India, subject to its procedural history.

The central objective of future genomic medicine law should be to enable safe and equitable medical innovation without turning a person's genetic identity into a basis for coercion, unjustified surveillance, or discrimination.

This is an academic overview, not jurisdiction-specific legal advice. The enforceability of each principle depends on current legislation, regulatory requirements, and binding judicial decisions in the relevant jurisdiction.